Palvella Therapeutics Uplists to Nasdaq Global Market After Meeting Higher Listing Standards
PVLA•Palvella received Nasdaq approval to transfer its stock from the Capital Market to the Global Market effective May 13, 2026, after meeting higher listing standards for financial metrics, public float and liquidity. The move enhances Palvella’s visibility as it advances QTORIN™ therapies for rare skin diseases and vascular malformations.
1. Uplisting Approval and Effective Date
Palvella obtained Nasdaq approval to transfer its common shares from the Capital Market to the Global Market, with the change taking effect at the opening of trading on May 13, 2026.
2. Higher Listing Standards Achieved
The company satisfied the Global Market’s stricter criteria, including minimum public float, bid price, stockholders’ equity thresholds, liquidity requirements and enhanced corporate governance standards.
3. Expected Market Impact
The uplisting is designed to boost Palvella’s profile among institutional investors, improve trading liquidity and support access to capital as it advances its clinical development programs.
4. QTORIN™ Pipeline Overview
Palvella’s pipeline includes QTORIN™ 3.9% rapamycin gel in trials for microcystic lymphatic and cutaneous venous malformations and QTORIN™ pitavastatin targeting disseminated superficial actinic porokeratosis.
